Americas · General news · Toronto Star

Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B ...

Published by Toronto Star · Canada 8 h ago

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery,…

Read the full article on Toronto Star Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.thestar.com)

Also worth reading

Global News

Blue Bombers beat Lions, clinch playoff spot

CBC News

U.S. Ambassador Pete Hoekstra offers Canada help following Wainwright tragedy

CTV News

'If you hold all the cards, you don't reshuffle the deck': Trade lawyer on Trump's trade comments

National Post

Hiromi Goto | National Post

France 24 Amériques

Présidentielle au Brésil : un entre-deux-tours aux allures de thriller psychologique

Le Devoir